Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Ameren Sells $900 Million Junior Subordinated Notes Due 2057

Ameren Corporation filed a Form 8-K with the SEC on September 18, 2026, reporting the sale of $900 million principal amount of Junior Subordinated Notes due 2057 and attaching related transaction documents as exhibits.

Aakashdeep | 18 September 2026

Why Is Nanobiotix (NASDAQ:NBTX) Stock Down 7% Today?

Nanobiotix (NASDAQ:NBTX) shares pulled back sharply in Friday's session as investors booked profits and digested mixed new clinical data, following a rally that had taken shares up roughly 283% over the past year. Nanobiotix is a Paris-based, late clinical-stage biotechnology company pioneering physics-based nanotherapeutics, …

Nitish Kishor | 18 September 2026

Why Is Xenon Pharmaceuticals (NASDAQ:XENE) Stock Down 30% Today?

Xenon Pharmaceuticals (NASDAQ:XENE) shares extended their decline through Friday's session, falling as much as 30.39% by the afternoon after opening the day down roughly 24% following the company's disclosure of a voluntary pause in new patient enrollment for its azetukalner studies in major depressive …

Nitish Kishor | 18 September 2026

Why Is XORTX Therapeutics (NASDAQ:XRTX) Penny Stock Rising 14% Today?

XORTX Therapeutics (NASDAQ:XRTX) shares jumped in Friday's session after the company outlined its anticipated Investigational New Drug application submission to the FDA for its XRx-026 gout program, planned for the fourth quarter of 2026. XORTX is a late-stage clinical pharmaceutical company headquartered in Calgary, …

Nitish Kishor | 18 September 2026

Alaunos Therapeutics (NASDAQ:TCRT) Prices Registered Direct Offering at $1.46 Per Share

Alaunos Therapeutics, Inc. (Nasdaq:TCRT) has priced a registered direct offering, agreeing to sell 380,469 shares of common stock alongside pre-funded warrants covering up to an additional 386,654 shares. The offering price of $1.46 per share was set at-the-market underNasdaqrules, and the transaction is expected …

Nitish Kishor | 18 September 2026

Halozyme Therapeutics (NASDAQ:HALO) Prices Upsized $1.3 Billion Convertible Notes Offering

Halozyme Therapeutics, Inc. (Nasdaq:HALO) has priced 1.3 billion dollars in aggregate principal amount of convertible senior notes due 2033, carrying a 1.50% annual interest rate. The offering size was increased from an originally announced 1.05 billion dollars, with initial purchasers also granted an option …

Nitish Kishor | 18 September 2026

BlossomHill Therapeutics (NASDAQ:BLSM) Reports Q2 2026 Results Following $168.3 Million IPO

BlossomHill Therapeutics, Inc. (Nasdaq:BLSM), a clinical-stage oncology company, has reported financial results for the second quarter of 2026, its first as a publicly traded company following an initial public offering completed in August. The IPO generated approximately 168.3 million dollars in gross proceeds through …

Nitish Kishor | 18 September 2026

XORTX Therapeutics (NASDAQ:XRTX) Plans FDA IND Submission for Gout Candidate XRx-026

XORTX Therapeutics Inc. (NASDAQ:XRTX), a late-stage clinical pharmaceutical company, has outlined plans to submit an Investigational New Drug application to the FDA in the fourth quarter of 2026 for its XRx-026 gout program. The filing represents a defined step in the company's broader strategy …

Nitish Kishor | 18 September 2026

Corcept Therapeutics (NASDAQ:CORT) Receives Positive CHMP Opinion for Lifyorli in Ovarian Cancer

Corcept Therapeutics Incorporated (NASDAQ:CORT) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, recommending that the European Commission approve relacorilant, marketed as Lifyorli, in combination with nab-paclitaxel chemotherapy for platinum-resistant ovarian cancer. The recommendation moves the …

Nitish Kishor | 18 September 2026

Why Is Alkermes (NASDAQ:ALKS) Stock Down 6% Today?

Alkermes (NASDAQ:ALKS) shares fell sharply in Friday's session, sharply underperforming the broader healthcare sector, which has been relatively firm amid a market rebound following the Federal Reserve's rate decision. Alkermes is a fully integrated, Dublin, Ireland-headquartered biopharmaceutical company that develops, manufactures, and commercializes medicines …

Nitish Kishor | 18 September 2026
Support

Hi! How can we help you today?

Loading…